Disclaimer: This article is intended for educational and research purposes only. CertaPeptides supplies research-grade peptides strictly for in vitro and preclinical investigation. Nothing in this article constitutes medical advice or a recommendation for human use.
Eli Lilly’s TRIUMPH clinical program continues to reshape the landscape of metabolic peptide research. In early 2026, the company reported positive topline results from TRIUMPH-4, a pivotal Phase 3 trial evaluating retatrutide — the first-in-class triple hormone receptor agonist — in adults with obesity and symptomatic knee osteoarthritis. The data are striking: up to 23.7% mean body weight reduction at the 12 mg dose, alongside clinically meaningful improvements in osteoarthritis pain scores. These findings position retatrutide as the most potent investigational weight-loss compound in late-stage development and a potential next-generation successor to dual-agonist therapies like tirzepatide.
Below, we break down the key data from TRIUMPH-4, contextualize retatrutide’s mechanism, compare efficacy across the incretin class, and outline what researchers should watch for as additional readouts arrive throughout 2026.
TRIUMPH-4 Results at a Glance
Key Outcomes — TRIUMPH-4 Phase 3 Trial
- Trial ID: NCT05929066
- Population: Adults with obesity (BMI ≥30) and symptomatic knee osteoarthritis
- Duration: 88 weeks (treatment period)
- Weight loss (9 mg): −20.0% vs −4.6% placebo
- Weight loss (12 mg): −23.7% (−27.2 kg absolute) vs −4.6% placebo
- Osteoarthritis pain (WOMAC): Up to 75.8% reduction (4.5-point improvement)
- Route: Once-weekly subcutaneous injection
- Status: Phase 3 complete; 7 additional TRIUMPH readouts expected in 2026
These results represent a statistically significant and clinically meaningful improvement over placebo on both co-primary endpoints: percent change in body weight and WOMAC pain subscale score. The magnitude of weight loss at the 12 mg dose exceeds what has been reported in pivotal trials for currently approved GLP-1 receptor agonists.
What Makes Retatrutide Different — Triple Receptor Agonism
Most investigational and approved weight-management peptides target one or two receptors in the incretin signaling pathway. Semaglutide (Wegovy/Ozempic) is a selective GLP-1 receptor agonist. Tirzepatide (Mounjaro/Zepbound) advanced the field by combining GIP and GLP-1 receptor activity into a single molecule — a “twincretin” approach that demonstrated superior efficacy in the SURMOUNT trial program.
Retatrutide goes one step further. Designated LY3437943, it is the first molecule to simultaneously engage three metabolic hormone receptors:
- GIP (glucose-dependent insulinotropic polypeptide) receptor — Enhances insulin secretion and may influence adipose tissue energy expenditure.
- GLP-1 (glucagon-like peptide-1) receptor — Reduces appetite, slows gastric emptying, and improves glycemic control. The well-established mechanism behind semaglutide and liraglutide.
- Glucagon receptor — This is the novel addition. Glucagon receptor activation promotes hepatic lipid oxidation, increases energy expenditure, and enhances thermogenesis. In preclinical models, glucagon agonism has been shown to drive additional fat mass reduction beyond what GLP-1 alone achieves.
The inclusion of glucagon receptor activity is what researchers believe drives retatrutide’s superior weight loss efficacy. The Phase 2 trial, published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2301972), demonstrated up to 24.2% weight reduction at 48 weeks — results that generated significant interest in the metabolic research community and prompted the expansive TRIUMPH Phase 3 program.
For researchers studying incretin receptor pharmacology, retatrutide represents a unique tool for investigating the synergistic effects of triple agonism on metabolic pathways, energy homeostasis, and body composition.
Weight Loss Efficacy Data
To contextualize the TRIUMPH-4 results, the table below compares weight loss outcomes across the three major investigational and approved GLP-1 class compounds based on their respective pivotal Phase 3 trials:
| Compound | Mechanism | Phase 3 Trial | Max Weight Loss | Duration |
|---|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | STEP 1 | −14.9% | 68 weeks |
| Tirzepatide 15 mg | GIP + GLP-1 | SURMOUNT-1 | −20.9% | 72 weeks |
| Retatrutide 12 mg | GIP + GLP-1 + Glucagon | TRIUMPH-4 | −23.7% | 88 weeks |
Note: Cross-trial comparisons should be interpreted with caution due to differences in study populations, trial duration, baseline characteristics, and endpoints. Head-to-head trials would be required for definitive comparative conclusions.
The progression from single to dual to triple receptor agonism has yielded incrementally greater weight reduction in each generation. The addition of glucagon receptor activation in retatrutide appears to unlock an additional 3-5 percentage points of body weight loss compared to tirzepatide’s dual-agonist approach. The absolute weight loss of 27.2 kg at the 12 mg dose in TRIUMPH-4 is particularly notable.
The Phase 2 data published in the NEJM showed that weight loss with retatrutide had not plateaued at 48 weeks, suggesting the 88-week TRIUMPH-4 data captures a more complete treatment trajectory. This non-plateau trajectory is an active area of research interest, as it may have implications for optimal treatment duration protocols.
Beyond Weight Loss — Osteoarthritis and Metabolic Benefits
What distinguishes TRIUMPH-4 from other obesity trials is its co-primary endpoint evaluating knee osteoarthritis outcomes. Obesity is a well-established risk factor for osteoarthritis, and the mechanical and inflammatory burden of excess body weight accelerates joint degeneration. The trial specifically enrolled participants with both obesity and symptomatic knee osteoarthritis to evaluate whether weight reduction with retatrutide would translate to meaningful joint pain improvement.
The results were compelling:
- WOMAC pain subscale reduction: Up to 75.8% improvement (4.5-point reduction on the validated WOMAC scale) at the 12 mg dose
- Improvements exceeded placebo responses by a statistically significant margin
- Both the 9 mg and 12 mg dose groups showed clinically relevant osteoarthritis benefit
This dual-benefit profile — simultaneous treatment of obesity and its musculoskeletal comorbidities — addresses a critical unmet need in metabolic research. Osteoarthritis affects over 500 million people globally, and obesity-related knee osteoarthritis represents one of the most common causes of disability in aging populations.
The broader TRIUMPH program (NCT05931367 and related registrations) also includes studies evaluating retatrutide’s effects on obstructive sleep apnea (OSA), cardiovascular outcomes, and metabolic parameters including liver fat content, which earlier Phase 2 data suggested may be reduced by up to 80-90% — a finding of considerable interest to researchers studying metabolic-associated steatotic liver disease (MASLD).
Safety Profile and Adverse Events
The safety data from TRIUMPH-4 are consistent with the known class effects of incretin-based therapies. Gastrointestinal adverse events were the most commonly reported side effects, which aligns with the mechanism of action affecting gut motility and appetite regulation:
| Adverse Event | Retatrutide (9-12 mg) | Placebo |
|---|---|---|
| Nausea | 38–43% | ~10% |
| Diarrhea | 33–35% | ~12% |
| Constipation | 22–25% | ~6% |
These gastrointestinal effects are characteristic of the GLP-1 receptor agonist class and were generally mild to moderate in severity. Most events occurred during the dose-escalation phase and diminished over time. The slow titration schedule used in the TRIUMPH program was designed to mitigate the severity and frequency of GI side effects.
Importantly, no new safety signals were identified relative to the Phase 2 trial. The addition of glucagon receptor agonism did not appear to introduce unexpected adverse events beyond the known GI class effects. Detailed safety data, including hepatic, pancreatic, and cardiovascular safety parameters, are expected to be published in the full peer-reviewed manuscript.
Researchers evaluating retatrutide in preclinical models should note that the GI side effect profile may be relevant when designing in vivo dosing protocols and should consult published dosing guidelines from the Phase 2 NEJM publication.
The Road Ahead — Remaining TRIUMPH Studies in 2026
TRIUMPH-4 is one of the first Phase 3 readouts in what is the largest clinical development program for a next-generation incretin therapy. Eli Lilly has disclosed that seven additional Phase 3 TRIUMPH trial readouts are expected throughout 2026, covering a range of metabolic conditions and populations:
- TRIUMPH-1: Obesity without type 2 diabetes (primary weight loss trial)
- TRIUMPH-2: Obesity with type 2 diabetes
- TRIUMPH-3: Obstructive sleep apnea (OSA) related to obesity
- TRIUMPH-5 through TRIUMPH-8: Additional populations and comorbidity studies, including cardiovascular outcomes
The breadth of the TRIUMPH program reflects Lilly’s strategy to position retatrutide across the full spectrum of obesity-related conditions — mirroring the expansive clinical programs that supported tirzepatide’s approval across multiple indications. If results are consistently positive, regulatory submissions for obesity indications could begin in late 2026 or early 2027.
The peptide therapeutics market continues its rapid expansion, with Grand View Research projecting the global market to reach $300 billion by 2033. Incretin-based therapies represent the fastest-growing segment, driven by the unprecedented efficacy of newer multi-agonist compounds. For the research community, this creates both commercial opportunity and scientific urgency to understand the mechanistic underpinnings of triple receptor agonism.
For a broader overview of GLP-1 receptor agonist research, including mechanism comparisons and assay considerations, see our comprehensive GLP-1 research guide.
Frequently Asked Questions
What is retatrutide’s mechanism of action?
Retatrutide (LY3437943) is a first-in-class triple agonist that simultaneously activates the GIP, GLP-1, and glucagon receptors. This triple mechanism is hypothesized to drive greater energy expenditure and fat oxidation compared to single or dual agonists. The GIP and GLP-1 components enhance insulin secretion and reduce appetite, while the glucagon component promotes hepatic lipid metabolism and thermogenesis. The Phase 2 mechanism and dose-response data were published in the NEJM (Jastreboff et al., 2023).
How does retatrutide compare to tirzepatide and semaglutide in research settings?
In clinical trials, retatrutide has demonstrated the highest magnitude of weight reduction among the three compounds: approximately 23.7% at the 12 mg dose (TRIUMPH-4), compared to 20.9% for tirzepatide 15 mg (SURMOUNT-1) and 14.9% for semaglutide 2.4 mg (STEP 1). However, direct cross-trial comparisons have limitations, and head-to-head studies would be necessary for definitive conclusions. Each compound offers distinct pharmacological profiles for research applications, with retatrutide uniquely enabling investigation of glucagon receptor contributions to metabolic outcomes. CertaPeptides offers both retatrutide and tirzepatide for in vitro research purposes.
When will full TRIUMPH-4 results be published?
As of March 2026, Eli Lilly has released topline results from TRIUMPH-4. Full results are typically presented at major medical conferences (such as the American Diabetes Association Scientific Sessions or ObesityWeek) before publication in peer-reviewed journals. Seven additional TRIUMPH Phase 3 readouts are expected throughout 2026. Researchers can monitor updates via ClinicalTrials.gov (NCT05929066).
Where can I obtain retatrutide for research purposes?
CertaPeptides supplies research-grade retatrutide (5 mg) and retatrutide (2 mg) for in vitro and preclinical investigation. All products include a Certificate of Analysis (COA) with purity verification. Our Retatrutide Starter Kit provides a cost-effective option for initial research protocols. All CertaPeptides products are sold exclusively for research purposes and are not intended for human consumption.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity and Osteoarthritis of the Knee (TRIUMPH-4). Identifier: NCT05929066.
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity (TRIUMPH-1). Identifier: NCT05931367.
- Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
- Grand View Research. Peptide Therapeutics Market Size, Share & Trends Analysis Report. 2024.
Research Use Disclaimer: All peptides supplied by CertaPeptides are intended strictly for in vitro research and laboratory use. They are not intended for human or animal consumption, therapeutic application, or diagnostic use. Researchers are responsible for compliance with all applicable regulations in their jurisdiction. The clinical trial data discussed in this article pertains to Eli Lilly’s investigational drug program and does not imply equivalence with research-grade reference compounds.